is a biotechnology
company specializing in vaccines
. The firm, a subsidiary of Johnson & Johnson
, is headquartered in Leiden
. Crucell shares were previously listed on the Euronext
and formed part of the AMX index
until April 2011, when J&J completed a tender offer
for the company.
In 1993 Introgene
, Crucell’s predecessor, was established as a spin-off
of Leiden University
. The company formed a partnership with Genzyme
to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics
as a joint venture together with Tibotec
. In 2000 IntroGene acquired U-Bisys
to form Crucell.
In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.
On 7 January 2009 Crucell released a press release
saying Crucell and Wyeth
were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer
's acquisition of Wyeth.
On 28 September 2009 Johnson & Johnson
bought 18% stake in Crucell for €302 milion in order to collaborate on the development of a flu vaccine
. This follows in the wake of Crucell's discovery of CR6261
, a potent human antibody that neutralizes a broad range of influenza... Read More